

Review

Applications of iPSC-derived beta cells from patients with diabetes

Kristina G. Maxwell^{1,2} and Jeffrey R. Millman^{1,2,3,*}

¹Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, MO 63110, USA

²Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA

³Twitter: @JeffreyRMillman

*Correspondence: jmillman@wustl.edu

<https://doi.org/10.1016/j.xcrm.2021.100238>

SUMMARY

Improved stem cell-derived pancreatic islet (SC-islet) differentiation protocols robustly generate insulin-secreting β cells from patient induced pluripotent stem cells (iPSCs). These advances are enabling *in vitro* disease modeling studies and the development of an autologous diabetes cell replacement therapy. SC-islet technology elucidates key features of human pancreas development and diabetes disease progression through the generation of pancreatic progenitors, endocrine progenitors, and β cells derived from diabetic and nondiabetic iPSCs. Combining disease modeling with gene editing and next-generation sequencing reveals the impact of diabetes-causing mutations and diabetic phenotypes on multiple islet cell types. In addition, the supply of SC-islets, containing β and other islet cell types, is unlimited, presenting an opportunity for personalized medicine and overcoming several disadvantages posed by donor islets. This review highlights relevant studies involving iPSC- β cells and progenitors, encompassing new conclusions involving cells from patients with diabetes and the therapeutic potential of iPSC- β cells.

INTRODUCTION

Diabetes is a disease diagnosed in >451 million patients worldwide.¹ This epidemic is caused by the death and dysfunction of pancreatic, insulin-secreting β cells. The current treatments for patients with type 1 diabetes, constituting ~10% of diabetes mellitus diagnoses, include exogenous insulin injections and cadaveric donor islet transplantation.^{2,3} Long-term exogenous insulin is commonly accompanied by hyperglycemia and hypoglycemia events, which can cause cardiovascular and kidney complications.⁴ A cell therapy pipeline developed from cadaveric islet transplantation emphasizes the potential power of cell replacement technology to enhance the quality of life for patients with diabetes. However, there is a limited supply of cadaveric donors and a need for immunosuppression.^{5,6} An alternate promising source for diabetes cell therapy is self-renewable human pluripotent stem cells (hPSCs).

Stem cell-derived definitive endoderm (DE), pancreatic progenitors (PPs), and endocrine progenitors (EPs) were created starting in 2006.⁷⁻⁹ These initial differentiation stages were critical to create stem cell-derived β (SC- β) cells and continue to be the initial stages in several differentiation protocols. SC- β cells were first generated in 2014 from embryonic stem cells (ESCs), with several key β cell characteristics capable of reversing diabetes in mouse models several weeks after transplantation.^{10,11} Recent advances in differentiation protocols have enabled the robust generation of SC- β cells from patient induced pluripotent stem cells (iPSCs).¹²⁻¹⁴ The new, refined protocols generated cell populations commonly called SC-is-

lets due to the composition consisting of almost all endocrine (chromogranin A⁺) cells, including glucagon⁺ alpha (SC- α) and somatostatin⁺ delta (SC- δ) cells. Patient-derived diabetic iPSC- β cells allow for disease progression studies of pancreatic and EPs during stages 4 and 5 of differentiation, benefiting many groups studying diabetes from patient stem cells due to the unknown presence and progression of diabetes at early development stages. In addition, studying patient SC- β cells with a known diabetic genotype at the final cell fate in stage 6 is effective for the diabetes field, drug screening, and future therapeutics. Furthermore, disease modeling with patient cells allows for a better understanding of multiple forms of diabetes, such as type 1 (T1D), type 2 (T2D), cystic fibrosis-related diabetes (CFRD), and monogenic diabetes (MD).³ Genetic engineering tools have been applied to patient iPSC-islets to generate nondiabetic (ND) phenotype and transgenic cell lines. Specifically, our group and colleagues used gene editing to correct MD variants found in neonatal diabetes (NeoD), maturity-onset diabetes of the young (MODY), and Wolfram syndrome (WS).¹⁵⁻¹⁷ Results from these studies demonstrated the potential for an autologous diabetes cell therapy. Microfluidic devices also present an opportunity for improved culture systems and drug screening platforms to study diabetes *in vitro*.¹⁸ Stem cell technology holds immense potential as a cell therapy to combat diabetes. This review summarizes the present literature on iPSC-islets from patients with diabetes by analyzing diabetes modeling and cell therapy development to highlight the potential of personalized therapy.






Figure 1. Applications of SC-islets from patients with diabetes

Patient tissue biopsies can be reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into stem cell-derived islets (SC-islets) that contain β (SC- β) cells. These SC-islets have applications in disease modeling, gene editing, and cell therapy in animal models. They also provide a source for autologous cell replacement therapy for patients with diabetes. DE, definitive endoderm; EP, endocrine progenitor; PGT, primitive gut tube; PP, pancreatic progenitor.

GENERATION EFFICIENCY OF iPSC-ISLETS FROM MULTIPLE DIFFERENTIATION PROTOCOLS

Differentiation protocols for SC-islets generally target the same developmental stages, beginning with DE and primitive gut tube, then narrowing cell fate to pancreatic and EPs, and ultimately targeting the final differentiated β cell.^{7,8,10–14} Small molecules and growth factors are typically used to navigate the pathways needed for the differentiation stages, aiming to mimic embryonic development. β cell and progenitor stem cell differentiation protocols have been meticulously developed over the past decade, beginning with DE and leading to functional SC- β cells, which have been reviewed previously.^{19–23} Alternatively, Sui et al.²⁴ used nuclear transfer embryonic stem (NT-ES) cells to generate NT-ES- β cells. Favorable off targets were commonly produced during the protocol, including α and δ cells. The presence of all main islet endocrine cell types led the field to rename SC- β cell clusters to SC-islets.^{17,25,26} Enterochromaffin (SC-EC) cells were recently identified as an off target generated in SC-islet differentiations that persist *in vivo*, validated by multiple groups.^{25,26} SC-EC cells are an endocrine (CHGA $^{+}$) cell type, and their effect on SC-islet function and maturation is unknown.²⁵ In addition, adverse off target cell types, such as neural progenitor cells (NPCs), pancreatic exocrine (mesenchyme, acinar), and polyhormonal (PH) cells, can contaminate the final cell cluster. Differentiation efficiency, genetic background, and disease state of the hPSCs influenced the composition proportions of these off targets.^{15,17,25}

Before the recent β cell differentiation protocols, iPSCs were unable to differentiate into SC- β cells as efficiently as ESCs. Protocols were typically optimized for a single ESC line, producing iPSC- β cells at lower efficiencies.^{10,11,14} SC- β or SC- β -like cells ranged from 17%²⁷ to 73%¹⁴ C-Peptide $^{+}$, a proxy marker for in-

sulin, at the final stage of differentiation. Of note, C-Peptide $^{+}$ cells can include both functional (NKX6.1 $^{+}$ C-Peptide $^{+}$) cells and PH (GCG $^{+}$ C-Peptide $^{+}$ and SST $^{+}$ C-Peptide $^{+}$) cells, which are nonfunctional and immature endocrine cells. Protocols with smaller cell yields used GFP reporter cell lines to create higher-purity β cell clusters based on β cell markers such as insulin, NKX6.1, or CD177.^{13,28,29} Purifying methods enabled the study of diabetes-relevant β cells for disease modeling *in vitro* and transplanting β cells *in vivo*.

Innovative refinements to remove off target cells during the EP stage used latrunculin A, an actin cytoskeleton modulator, to enrich the endocrine population.^{12,17} This protocol provided an opportunity to perform the SC-islet differentiation in planar in 6 stages, reducing technical expertise and costly equipment for three-dimensional (3D) culture. In addition, the removal of function-inhibiting small molecules and reaggregation in the final differentiation stage enhanced the function of SC-islets and showcased the rapid reversal of diabetes in rodent models with patient SC- β cells.^{13,14} The improved protocols required minimal optimization of multiple patient iPSC lines for successful differentiations. The SC-islets contained almost pure endocrine cell populations.¹² We and our colleagues can now readily investigate SC-islets from patients with diabetes.

DISEASE MODELING WITH iPSCs FROM PATIENTS WITH DIABETES

SC-islets from patients with diabetes are critical to gain a better understanding of the disease and its progression. Thus, iPSCs have been reprogrammed from patients with T1D, T2D, MODY, CFRD, WS, and NeoD (Figure 1; Tables 1 and 2). Typically, the Yamanaka factors (OCT4, KLF4, SOX2, c-MYC) were

Table 1. Summary of T1D and T2D patient iPSC cell line studies for diabetes-in-a-dish

Study reference	Diabetic state	Cell type generated	In vivo transplantation	Additional notes
Leite et al. (2020) ³²	T1D	SC-β and SC-α cells	no	isogenic co-culture with immune cells
Wang et al. (2019) ³³	T2D	β-like cells	no	microarray, RNA-seq, and ChIP-seq data from PPs
Dwivedi et al. (2019) ³⁴	T2D	β-like cells	–	RNA-seq
Sui et al. (2018) ²⁴	T1D	NT-iPSC-β cells	yes, prevent diabetes onset	NT patient SCs
Cosentino et al. (2018) ²⁷	T2D	β-like cells	no	–
Amin et al. (2018) ³⁵	T1D, T2D	SC-β cells	yes, study <i>in vivo</i> cells	chemical screen, RNA-seq of sorted β sorted cells
Millman et al. (2016) ³⁶	T1D	SC-β cells	yes, prevent diabetes onset	microarray data
Thatava et al. (2013) ³⁷	T1D	Pancreatic islet-like cells	–	microarray data of iPSCs

used to reprogram the somatic cells through either retrovirus, Sendai virus, or episomal reprogramming.^{30,31} Alternatively, Sui et al.²⁴ used somatic cell NT to generate T1D NT-ESCs from skin fibroblasts. Studies differentiated patient iPSCs into SC-β cells and progenitors, and investigated cell maturation, differentiation efficiencies, and insulin secretion function. When differences were found, they typically occurred after pancreatic cell fate was designated. The cells were commonly compared to either nondiabetic or gene-edited isogenic controls. Genetic engineering is used to reverse these effects and correct the known diabetes, causing mutations.

T1D and T2D are the most common forms of diabetes mellitus, constituting ~10% and 90% of patients with diabetes, respectively.³ Understanding the pathophysiology of these diseases is complex due to risk factors, including epigenetics, environment, and lifestyle. Many rodent models of T1D and T2D exist; however, there are several physiologic differences between rodents and humans, specifically in the islets.^{44,45} Therefore, we and others used stem cell technology to create iPS cells from human patients to model T1D and T2D and gain a better understanding of disease pathogenesis (Table 1). Early studies used PDX1⁺NKX6-1⁺ PPs, which give rise to all pancreatic cell fates. T1D iPSC-β cells functioned and had differentiation efficiencies similar to ND iPSC-β cells,³⁶ which is consistent with previous reports comparing T1D and ND SC-PPs.³⁷ Under further investigation, *in vitro* modeling systems revealed that T1D patient-derived endocrine cells respond to stress³⁶ and react to autologous immune cells in a cell-type-specific manner, providing a better understanding of T1D pathogenesis.³² There is no literature investigating SC-islets from patients with T2D; however, T2D iPSCs are available.³⁰ There are multiple studies using patient iPSCs with T2D-risk variants including SLC30A8,³⁴ TRMT10A,²⁷ and PDX1.³³ To further study T2D, next-generation sequencing (NGS) identified gene expression differences in T2D primary human islets compared to healthy controls.^{46,47} Xin et al.⁴⁸ reported differentially expressed genes found in the main endocrine islet cell types. Specifically, in β cells, PAXBP-1, GLS2, and FXYD23 are upregulated and G6PC2, GLRA1, and IGFBPL1 are downregulated.

CFRD and MD are rarer forms of diabetes that limit the availability of primary samples. Thus, patient iPSCs are critical for uncovering disease pathogenesis and therapeutic development. Pancreatic ductal epithelial cells were derived from iPSCs with a CF genetic background, creating a drug screening platform *in vitro*.⁴⁹ MD is caused by a single gene mutation that occurs in roughly 2% of patients who are diagnosed with diabetes mellitus (reviewed by Harris et al.⁵⁰). Patient iPSCs from MODY, NeoD, and WS backgrounds have allowed for human MD modeling. Recent publications investigated mutations in PDX1, GLIS3, HNF1A, HNF1B, GCK, INS, GATA6, SUR1, and WFS1, which are each related to a form of MD (Table 2). Genetic engineering tools were commonly applied to correct the known mutation in an isogenic cell line, which often led to a healthy phenotype (Table 2).^{15,17,33,34,35,38,39,42} Diabetic SC derivatives were typically less efficient in generating SC-islets, SC-β cells, and SC-PPs. This occurred when evaluating mutations in GATA6,⁴⁰ WFS1,^{17,42} and PDX1³³ (Table 2). However, the SUR1 mutation caused the inactivation of the K_{ATP} channel, resulting in congenital hyperinsulinism (CHI) and eventually MODY, producing an increased number of SC-β-like cells with greater function.³⁸ Transplantation was commonly performed to observe cell maturation *in vivo* and examine whether cells could either reverse preexisting diabetes or prevent diabetes induction in mice (Table 2). In summary, human iPSC differentiation protocols enable the study of diabetic β cells and progenitors *in vitro*.

INSIGHTS IN STEM CELL-DERIVED ISLETS FROM NGS OF iPSCS

Several iPSC studies used NGS strategies^{15,17,33} and microarrays^{36,37,40,51} to study differentially expressed genes in specific islet cell types, such as α and β cells. Balboa et al.¹⁵ and Maxwell et al.¹⁷ used single-cell NGS, and both studies observed increases in β cell genes for gene-edited SC-β-like and SC-β cells. Wang et al.³³ identified downregulated PDX1-bound genes that reduce differentiation efficiency, including MNX1, CES1, and MEG3. Millman et al.³⁶ identified TAP1 as the largest

Table 2. Summary of studies investigating known diabetes variants for T1D, T2D, and MD

Study reference	Diabetic state	Variant of interest	Cell type generated	Genetic engineering	In vivo transplantation	Additional notes
Lithovius et al. (2020) ³⁸	CHI/MODY	SUR1	β-like cells	yes, CRISPR/Cas9 to correct mutation	yes, study <i>in vivo</i> cells	–
Maxwell et al. (2020) ¹⁷	WS	WFS1	SC-β cells	yes, CRISPR/Cas9 to correct variant	yes, reverse preexisting diabetes	Single-cell RNA-seq
Cardenas-Diaz et al. (2019) ³⁹	MODY3	HNF1A	β-like cells	yes, CRISPR/Cas9 to introduce HET and homozygous KO mutations	no	microarray of INS-GFP ⁺ NKX6.1 ⁺ cells
Wang et al. (2019) ³³	T2D	PDX1	β-like cells	yes, CRISPR/Cas9 to introduce HET and homozygous KO mutations in iPSC line	no	microarray, RNA-seq, and ChIP-seq data from PPs
Dwivedi et al. (2019) ³⁴	T2D	ZnT8	β-like cells	yes, CRISPR/Cas9 to introduce protective alleles into SLC30A8 locus	yes, study <i>in vivo</i> cells	RNA-seq
Balboa et al. (2018) ¹⁵	NeoD	INS	β-like cells	yes, CRISPR/Cas9 to correct variant	yes, study <i>in vivo</i> cells	single-cell RNA-seq
Kishore et al. (2020) ⁴⁰	adult-onset diabetes	GATA6	β-like cells	yes, CRISPR/Cas9 to correct variant	no	ChIP-qPCR
Amin et al. (2018) ³⁵	T1D, T2D, NeoD	GLIS3	SC-β cells	yes, CRISPR/Cas9 to introduce GLIS3 mutations	yes, study <i>in vivo</i> cells	chemical screen, RNA-seq of sorted β sorted cells
Ma et al. (2018) ¹⁶	NeoD	INS	β-like cells	yes, CRISPR/Cas9 correction of variant	yes, prevent diabetes onset	–
Stepniewski et al. (2015) ⁴¹	MODY3	HNF1A	β-like cells	–	yes, tested iPSC tumor formation	–
Shang et al. (2014) ⁴²	WS	WFS1	insulin-producing cells	WT WFS1 lentivirus to correct variant	yes, prevent diabetes onset	tested ER chaperone drugs
Teo et al. (2013) ⁴³	MODY1	HNF4A	–	–	–	–
	MODY1	HNF4A	–	–	–	–
	MODY2	GCK	–	–	–	–
	MODY3	HNF1A	–	–	–	–
	MODY5	HNF1B	–	–	–	–
	MODY5	HNF1B	–	–	–	–
	MODY8	CEL	–	–	–	–

differentially expressed gene in T1D SC-β cells compared to healthy patients. Recently, Augsornworawat et al.²⁶ evaluated the transcriptome of transplanted SC-islets with single-cell RNA sequencing from both ESCs and iPSCs to show the strong resemblance of *in vivo* SC-islets and primary human islets. A maturation list for β and α cells was curated from the sequencing data, providing a resource of targets for β cell maturation *in vitro*.²⁶ NGS of primary human islets and SC-islets was previously reviewed and highlighted key findings for the differences between diabetic and nondiabetic human islets, as well as important islet cell type-defining gene signatures.⁵² Of note, Muraro et al.⁵³ and Segerstolpe et al.⁴⁶ characterized human islet samples from ND and T2D patients. Krentz et al.⁵⁴ and Hrvatin et al.⁵¹ compared progenitor cell types to human islets. Lastly, Veres et al.²⁵ profiled the various stages of differentiation to yield a potential cell sorting mechanism with CD49a and identified SC-

EC cells. Xin et al.⁴⁸ detailed the unfolded protein response in primary β cells from multiple donors. These studies used innovative biotechnology to perturb the transcriptome of primary and stem cell-derived human islets.

INSIGHTS ON DIABETES THROUGH DISEASE-IN-A-DISH STUDIES

- (1) SC-islets and progenitor derivatives are used to model diabetes-in-a-dish. Endoplasmic reticulum (ER) stress experiments are commonly applied to ND and diabetic SC-islets to represent diabetes *in vitro*.⁵⁵ In all forms of diabetes, ER stress is found in β cells, causing dysfunction and eventual unfolded protein response (UPR)-mediated cell death.⁵⁶ Balboa et al.,¹⁵ Shang et al.,⁴² and Maxwell et al.¹⁷ studied SC-β cells and progenitors from patients

with mutations linked to diabetes and known to cause ER stress. The results revealed a combination of increased protein and gene expression of ER stress markers, dysfunctional insulin processing, and reduced insulin secretion in response to glucose. Shang et al.⁴² and Maxwell et al.¹⁷ also showed dilated ER with electron microscopy, indicating ER stress. Balboa et al.¹⁵ and Maxwell et al.¹⁷ used NGS to identify increased ER stress (ATF6, BiP/HSPA5), apoptosis (CHOP, CASP3), and oxidative stress transcripts (TXNIP). SC- β cells with greater maturation compared to progenitors influenced ER stress and study results. As portrayed when comparing WS studies, SC- β cells¹⁷ were more mature than insulin-producing cells,⁴² indicated by the attainment of β cell markers and functional insulin secretion in response to glucose. Specifically, for WS studies, C-Peptide⁺ insulin-producing cell yields were not reduced with a WFS1 mutation; however, SC- β cells had lower yields when comparing the unedited and corrected iPSC differentiations. Greater insulin production supported higher functional capacity, and in return, increased ER stress due to increased insulin production and protein folding. The inability to handle elevated protein folding activated the unfolding protein response at a basal level and likely influenced differentiation from EPs to SC- β cells. There are few articles available examining ER stress in human islets^{48,57}; therefore, human SC-islets are a critical resource to understand diabetes-in-a-dish.

- (2) Transgenic cell lines are generated through editing technologies that insert and express foreign DNA. For diabetes research, transgenic stem cells were created using biotechnology to either study diabetes through the insertion of a known diabetes-causing variant or monitor differentiation with a reporter cell line. This technology advancement was critical to study known variants associated with T1D and T2D. Amin et al.³⁵ used a GLIS3 mutation associated with T1D, T2D, and NeoD to generate SC-PP2 and SC-PP2- β cells. With the mutation, they observed increased cell death and impaired differentiation compared to isogenic controls, developing a drug screening platform. Shang et al.⁴² transfected WT WFS1 lentivirus in their patient iPS-derived insulin-producing cells to model WS *in vitro*. Dwivedi et al.³⁴ inserted a ZnT8 loss-of-function (LoF) allele, expected to protect against T2D, using CRISPR/Cas9 in patient iPSCs and found increased glucose responsiveness, making ZnT8 a promising target for increased insulin secretion as a T2D treatment. Transgenic stem cell lines were also used to study neurologic, epidermal, and cardiomyocyte disorders.
- (3) Microfluidic devices are used to mimic the *in vivo* pancreas and islet microenvironment. Engineered devices perturbed islet function by enhancing insulin sensing, monitoring islet hormone secretion in response to glucose, and quantifying pulsatile insulin release. Misun et al.⁵⁸ generated a device to monitor dynamic insulin secretion of a single human islet. Lenguito et al.⁵⁹ combined convective fluidic devices and computational

modeling of glucose-stimulated insulin secretion (GSIS) to develop a competitive alternative to commercially available perfusion systems with the opportunity to image cells while in the machine. Jun et al.⁶⁰ and Sankar et al.⁶¹ developed a dynamic culture system as an alternative to typical static culture by integrating interstitial flow to better mimic *in vivo* islet conditions *in vitro*. Gieberman et al.⁶² designed a microfluidic device incorporating the native islet microenvironment by delivering pulsatile insulin through arteriole and capillary channels on a chip. This system also continuously monitored insulin release, quantified with fluorescence anisotropy. Future protocols may benefit from differentiating PSCs in these engineered culture devices, such as the integrated platform developed by Ishahak et al.⁶³ that incorporated continuous perfusion culture with the ability to monitor functional maturation. These newly developed devices are competitive platforms for drug screening and studying dynamic insulin secretion *in vitro*.

- (4) Sorting SC- β cells and progenitors are helpful in studying specific cell types of interest and removing off target cell types from differentiation protocols. Several studies used NKX6.1^{GFP/w} and INS^{GFP/w} stem cell lines to enhance SC- β cell yields.^{16,24,28,64} Mahaddalkar et al.⁶⁵ identified anterior DE markers CD177 and CD275 to specify pancreatic and liver fates, respectively. Thus, they sorted for CD177⁺CD275⁻ after DE was defined in the first stage of SC-islet differentiation, improving the percentage of INS⁺NKX6.1⁺ β -like cells at stage 7. To enrich functional cells, Li et al.⁶⁶ sorted human β -like cells for CD9, a cell-surface marker found in immature human β cells, to negatively enrich glucose-responsive cells. In addition, Veres et al.²⁵ recently identified CD49a/ITGA1 as a surface marker for β cells in SC-islet clusters, thereby increasing the insulin secretion of individual islets. Sorting strategies are beneficial to study β cells for disease-in-a-dish modeling of diabetes.

INSIGHTS IN DISEASE MECHANISM THROUGH GENE EDITING

Editing of genes important for β cell differentiation is commonly performed in the SC- β cell field to determine the effect on β cell insulin secretion. The impact of PDX1, MAFA, and NEUROG3 have been extensively studied in SC- β cells (review by Zhu et al.⁶⁷). Gene editing has also been proposed for cell therapy efforts in both correction of diabetes-causing mutations and resistance to immune rejection. We and other colleagues used CRISPR/Cas9 and lentiviral transduction to correct known diabetes-causing mutations in patient iPSCs. Maxwell et al.¹⁷ and Ma et al.¹⁶ used gene correction to reverse and prevent diabetes in mice, respectively. These results are very promising for the potential of an autologous cell therapy. Lithovius et al.³⁸ corrected the SUR1 mutant K_{ATP} activator and identified a role for the K_{ATP} channel in development by revealing increased insulin secretion and proliferation of the mutant compared to the isogenic gene-corrected SC- β -like cells. Enhanced function was expected as patients with CHI, and eventually MODY, are

unable to initiate membrane depolarization and continually secrete insulin.³⁸ Eichstadt et al.⁶⁸ used gene-corrected autologous cell therapy in a Phase I/IIa clinical trial for recessive dystrophic epidermolysis bullosa and observed no adverse effects. Río et al.⁶⁹ published results from a Phase I/II clinical trial of gene-corrected hematopoietic gene therapy for patients with Fanconi anemia and also detected no immune rejection effects. However, there remains concern that gene editing of autologous cells may cause immune rejection due to the autoimmune reactive nature of diabetes. Therefore, the current efforts investigating immune rejection resistance in allogeneic cell therapy may also be needed to a lesser extent for autologous cell therapy. Genome engineering to address immune intervention was previously reviewed.⁷⁰ For SC- β cell therapy, key targets for the genome engineering of diabetes cell therapy included human leukocyte antigen (HLA) modification to expand SC-islet utility and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programmed death-1/programmed death ligand-1 (PD-1/PD-L1) adjustment to target T cell immune rejection upon transplantation.^{71,72} Alternate iPSC-derived engineered cell types (endothelial, smooth muscle, cardiomyocytes) described by Deuse et al.⁷³ used major histocompatibility complex (MHC)-mismatched allogeneic sources to inactivate the MHC class I and II genes and overexpress CD47 with CRISPR/Cas9 to successfully evade immunosuppression in recipients. These advances in SC- β cell and alternate cell genetic engineering aim to address an unmet need in the autologous and allogeneic stem cell therapy field.

INSIGHTS ON *IN VIVO* CELL THERAPY WITH ANIMAL MODELS

To develop an adequate cell therapy, *in vivo* testing is needed in animal models for therapeutic validation. Our group and colleagues have established several studies confirming the use of SC-islets, SC- β cells, and PPs for cell therapy in rodent models. Validation methods included prevention of diabetes^{16,24,42,74,75} and diabetes reversal^{10,11,13,14,17} by transplanting cells in the kidney capsule before or after diabetes induction, respectively. Streptozotocin and alloxan induced diabetes in mouse and rat models. Nephrectomies were also commonly performed to confirm that the transplanted cells were the source of euglycemia in kidney capsule transplants.^{9,12,17,24,75,76} Several groups confirmed the maturation of SC-islets, SC- β cells, and PPs post-transplantation with immunostaining. Transplantation sites ranged from portal vein, intramuscular, and subcutaneous to kidney capsule.^{12,16,24,75} The impact on pregnancy and sex between mouse recipients revealed no differences between male and female mice.^{75,77} *In vivo* models were used to test encapsulation devices with stem cell-derived β -like cells and progenitors.^{75,78–81} Transplantation was typically assessed in immunocompromised mice due to immune rejection of SC-islets; however, Yoshihara et al.⁷² successfully transplanted and maintained glucose homeostasis in diabetic immunocompetent mice for 50 days, with their human islet-like organoids genetically engineered to overexpress PD-L1. These combined efforts for *in vivo* testing are encouraging that a diabetes cell therapy will soon be produced.

PERSONALIZED CELL REPLACEMENT THERAPY

The standard care of treatment for patients with T1D is exogenous insulin. Risks and complications involved with this treatment include hypoglycemia, swelling and infection at injection site, and weight gain. In addition, long-term exposure may increase cardiovascular complications, stroke risk, and kidney damage, due to uncontrolled hyperglycemic and hypoglycemic events.⁸² Experimental treatment methods currently in practice include pancreas and cadaveric islet transplantation.^{83–85} These methods were only used when a patient was unresponsive to standard treatment or kidney damage was present and the patient concurrently underwent kidney transplantation surgery. Cadaveric islet transplantations have limited donor availability and require multiple donors, resulting in donor-to-donor variation. Clinical trials are also under way by ViaCyte using allogeneic stem cell-derived PPs and an encapsulation device (NCT02239354 and NCT03163511) and planned by Vertex Pharmaceuticals using allogeneic SC-islets (NCT04786262). The transplantation of allogeneic cells and organs requires the recipient to be taking immunosuppressive drugs, which can be problematic for patients with T1D. SC-islets overcome several of these limitations, providing an unlimited cell source with robust function for use as a cell therapy. Autologous diabetes cell therapy is made possible with patient iPSC-islets, which contain their missing insulin-secreting β cells, and has the potential to remove the need for immunosuppressive drugs post-transplant. However, there is a financial concern regarding autologous cell therapies for a wide range of diseases. Once cell therapy is established as a safe and viable treatment for disease, measures to reduce costs will be used, allowing for mass cell product manufacturing. Protocol updates will enable the generation of large cell batches, enabling the cryopreservation of functional SC- β cells.⁷⁵ An additional concern is *de novo* mutations in mitochondrial DNA occurring in autologous iPSCs and leading to the production of neoantigens, dependent on MHC genotype.⁸⁶ With advances in stem cell technology, diabetes cell therapy can be used in a wider patient population, including insulin-independent patients with T1D and T2D and those undergoing a pancreatectomy.

FUTURE OUTLOOK

In general, there are technical difficulties and financial concerns related to iPSC therapy. To reduce the financial burden, biobanks of genome-stable iPSCs capable of matching the majority of HLA types⁸⁷ and rarer blood types⁸⁸ are being explored. This format would create more personalized medicine than allogeneic while also reduce the immunogenicity through HLA matching.⁸⁷ Biobanks would also ease the technical and costly difficulties of personalized medicine by creating banks of HLA-matched differentiated cell types using mass production. Genomic instability is an additional obstacle in iPSC therapy clinical translation. When reprogramming somatic cells to iPSCs, chromosomal aberrations or mutations often occur.⁸⁹ Furthermore, tumor formation remains a concern. While diabetes stem cell replacement therapy has several established protocols that have little to no detectable teratoma-forming cells,¹² many organs and differentiated cell

types necessary to address other diseases remain preliminary and will require several additional iterations before clinical translation can occur. However, genetic engineering of suicide genes to destroy transplanted cells upon tumor formation is being investigated.⁹⁰ After these obstacles are overcome and stem cell therapy is available in the clinical setting, the quality of life will be greatly increased for patients worldwide.

SC-islets are a promising renewable cell source for diabetes cell therapy that can be produced with recent differentiation protocols.^{12,13,25} While advances in SC-islet differentiation protocols are encouraging, a universal differentiation protocol adaptable to all iPSC lines would better facilitate autologous cell therapy. This would eliminate the costly and time-consuming optimization and difficulties that are often encountered with new cell lines. Genetic engineering tools could aid in advancing autologous diabetes cell therapy research. These tools could identify iPSC or early-stage markers that define suitability for an efficient SC-islet differentiation⁶⁵ or genes to overexpress in iPSCs to initiate or improve differentiation.⁹¹ In addition, reporters to enable robust readouts of function and maturation after cell fate specification would help both cell therapy development and drug screening applications.^{92–94} Ideally, SC-islets would be indistinguishable from primary islets for transplantation, specifically in terms of glucose-stimulated insulin secretion, but further protocol improvements are needed to achieve this.

ACKNOWLEDGMENTS

J.R.M. was supported by the NIH (R01DK114233 and R01DK127497), a JDRF Career Development Award (5-CDA-2017-391-A-N), and startup funds from the Washington University School of Medicine Department of Medicine. We thank Sarah Gale and Michelle Kim for editorial assistance and Cassandra Pinhas for graphic design.

AUTHOR CONTRIBUTIONS

K.G.M. and J.R.M. wrote, edited, and reviewed the manuscript.

DECLARATION OF INTERESTS

K.G.M. and J.R.M. are inventors on licensed patents and patent applications related to the SC-β cell technology described in this manuscript. J.R.M. is a consultant for Sana Biotechnology. K.G.M. is the chief operations officer and co-founder of Salentra Biosciences. J.R.M. is the chief scientific officer and co-founder of Salentra Biosciences.

REFERENCES

- Cho, N.H., Shaw, J.E., Karuranga, S., Huang, Y., da Rocha Fernandes, J.D., Ohrogge, A.W., and Malanda, B. (2018). IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res. Clin. Pract.* **138**, 271–281.
- Meloche, R.M. (2007). Transplantation for the treatment of type 1 diabetes. *World J. Gastroenterol.* **13**, 6347–6355.
- Kharroubi, A.T., and Darwish, H.M. (2015). Diabetes mellitus: the epidemic of the century. *World J. Diabetes* **6**, 850–867.
- Schwartz, S.S., Epstein, S., Corkey, B.E., Grant, S.F.A., Gavin, J.R., III, Aguilar, R.B., and Herman, M.E. (2017). A unified pathophysiological construct of diabetes and its complications. *Trends Endocrinol. Metab.* **28**, 645–655.
- Hering, B.J., Clarke, W.R., Bridges, N.D., Eggerman, T.L., Alejandro, R., Bellin, M.D., Chaloner, K., Czarniecki, C.W., Goldstein, J.S., Hunsicker, L.G., et al.; Clinical Islet Transplantation Consortium (2016). Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. *Diabetes Care* **39**, 1230–1240.
- Ryan, E.A., Paty, B.W., Senior, P.A., Bigam, D., Alfadhl, E., Kneteman, N.M., Lakey, J.R., and Shapiro, A.M. (2005). Five-year follow-up after clinical islet transplantation. *Diabetes* **54**, 2060–2069.
- D'Amour, K.A., Bang, A.D., Eliazer, S., Kelly, O.G., Agulnick, A.D., Smart, N.G., Moorman, M.A., Kroon, E., Carpenter, M.K., and Baetge, E.E. (2006). Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. *Nat. Biotechnol.* **24**, 1392–1401.
- D'Amour, K.A., Agulnick, A.D., Eliazer, S., Kelly, O.G., Kroon, E., and Baetge, E.E. (2005). Efficient differentiation of human embryonic stem cells to definitive endoderm. *Nat. Biotechnol.* **23**, 1534–1541.
- Kroon, E., Martinson, L.A., Kadoya, K., Bang, A.G., Kelly, O.G., Eliazer, S., Young, H., Richardson, M., Smart, N.G., Cunningham, J., et al. (2008). Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells *in vivo*. *Nat. Biotechnol.* **26**, 443–452.
- Pagliuca, F.W., Millman, J.R., Gürler, M., Segel, M., Van Dervort, A., Ryu, J.H., Peterson, Q.P., Greiner, D., and Melton, D.A. (2014). Generation of functional human pancreatic β cells *in vitro*. *Cell* **159**, 428–439.
- Rezania, A., Bruun, J.E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quisckamp, N., Mojibian, M., Albrecht, T., et al. (2014). Reversal of diabetes with insulin-producing cells derived *in vitro* from human pluripotent stem cells. *Nat. Biotechnol.* **32**, 1121–1133.
- Hogrebe, N.J., Augsornworawat, P., Maxwell, K.G., Velazco-Cruz, L., and Millman, J.R. (2020). Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells. *Nat. Biotechnol.* **38**, 460–470.
- Nair, G.G., Liu, J.S., Russ, H.A., Tran, S., Saxton, M.S., Chen, R., Juang, C., Li, M.L., Nguyen, V.Q., Giacometti, S., et al. (2019). Recapitulating endocrine cell clustering in culture promotes maturation of human stem-cell-derived β cells. *Nat. Cell Biol.* **21**, 263–274.
- Velazco-Cruz, L., Song, J., Maxwell, K.G., Goedegebuure, M.M., Augsornworawat, P., Hogrebe, N.J., and Millman, J.R. (2019). Acquisition of Dynamic Function in Human Stem Cell-Derived β Cells. *Stem Cell Reports* **12**, 351–365.
- Balboa, D., Saarimäki-Vire, J., Borshagovski, D., Survila, M., Lindholm, P., Galli, E., Eurola, S., Ustinov, J., Grym, H., Huopio, H., et al. (2018). Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes. *eLife* **7**, e38519.
- Ma, S., Viola, R., Sui, L., Cherubini, V., Barbetti, F., and Egli, D. (2018). β cell replacement after gene editing of a neonatal diabetes-causing mutation at the insulin locus. *Stem Cell Reports* **11**, 1407–1415.
- Maxwell, K.G., Augsornworawat, P., Velazco-Cruz, L., Kim, M.H., Asada, R., Hogrebe, N.J., Morikawa, S., Urano, F., and Millman, J.R. (2020). Gene-edited human stem cell-derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice. *Sci. Transl. Med.* **12**, eaax9106.
- Tran, R., Moraes, C., and Hoesli, C.A. (2020). Developmentally-Inspired Biomimetic Culture Models to Produce Functional Islet-Like Cells From Pluripotent Precursors. *Front. Bioeng. Biotechnol.* **8**, 583970.
- Nostro, M.C., and Keller, G. (2012). Generation of beta cells from human pluripotent stem cells: potential for regenerative medicine. *Semin. Cell Dev. Biol.* **23**, 701–710.
- Velazco-Cruz, L., Goedegebuure, M.M., and Millman, J.R. (2020). Advances Toward Engineering Functionally Mature Human Pluripotent Stem Cell-Derived β Cells. *Front. Bioeng. Biotechnol.* **8**, 786.
- Theis, F.J., and Lickert, H. (2019). A map of β-cell differentiation pathways supports cell therapies for diabetes. *Nature* **569**, 342–343.
- Aguayo-Mazzucato, C., and Bonner-Weir, S. (2010). Stem cell therapy for type 1 diabetes mellitus. *Nat. Rev. Endocrinol.* **6**, 139–148.

23. Tremmel, D.M., Mitchell, S.A., Sackett, S.D., and Odorico, J.S. (2019). Mimicking nature-made beta cells: recent advances towards stem cell-derived islets. *Curr. Opin. Organ Transplant.* 24, 574–581.
24. Sui, L., Danzl, N., Campbell, S.R., Viola, R., Williams, D., Xing, Y., Wang, Y., Phillips, N., Poffenberger, G., Johannesson, B., et al. (2018). β -Cell Replacement in Mice Using Human Type 1 Diabetes Nuclear Transfer Embryonic Stem Cells. *Diabetes* 67, 26–35.
25. Veres, A., Faust, A.L., Bushnell, H.L., Engquist, E.N., Kenty, J.H., Harb, G., Poh, Y.C., Sintov, E., Gürler, M., Pagliuca, F.W., et al. (2019). Charting cellular identity during human *in vitro* β -cell differentiation. *Nature* 569, 368–373.
26. Augsornworawat, P., Maxwell, K.G., Velazco-Cruz, L., and Millman, J.R. (2020). Single-Cell Transcriptome Profiling Reveals β Cell Maturation in Stem Cell-Derived Islets after Transplantation. *Cell Rep.* 32, 108067.
27. Cosentino, C., Toivonen, S., Diaz Villamil, E., Atta, M., Ravanat, J.L., Demine, S., Schiavo, A.A., Pachera, N., Deglasse, J.P., Jonas, J.C., et al. (2018). Pancreatic β -cell tRNA hypomethylation and fragmentation link TRMT10A deficiency with diabetes. *Nucleic Acids Res.* 46, 10302–10318.
28. Nostro, M.C., Sarangi, F., Yang, C., Holland, A., Elefanty, A.G., Stanley, E.G., Greiner, D.L., and Keller, G. (2015). Efficient generation of NKX6-1+ pancreatic progenitors from multiple human pluripotent stem cell lines. *Stem Cell Reports* 4, 591–604.
29. Russ, H.A., Parent, A.V., Ringler, J.J., Hennings, T.G., Nair, G.G., Shveygert, M., Guo, T., Puri, S., Haataja, L., Cirulli, V., et al. (2015). Controlled induction of human pancreatic progenitors produces functional beta-like cells *in vitro*. *EMBO J.* 34, 1759–1772.
30. Kudva, Y.C., Ohmine, S., Greder, L.V., Dutton, J.R., Armstrong, A., De Lamo, J.G., Khan, Y.K., Thatava, T., Hasegawa, M., Fusaki, N., et al. (2012). Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. *Stem Cells Transl. Med.* 1, 451–461.
31. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861–872.
32. Leite, N.C., Sintov, E., Meissner, T.B., Brehm, M.A., Greiner, D.L., Harlan, D.M., and Melton, D.A. (2020). Modeling Type 1 Diabetes *In Vitro* Using Human Pluripotent Stem Cells. *Cell Rep.* 32, 107894.
33. Wang, X., Sterr, M., Ansarullah, Burtscher, I., Böttcher, A., Beckenbauer, J., Siehler, J., Meitinger, T., Häring, H.U., Staiger, H., et al. (2019). Point mutations in the PDX1 transactivation domain impair human β -cell development and function. *Mol. Metab.* 24, 80–97.
34. Dwivedi, O.P., Lehtovirta, M., Hastoy, B., Chandra, V., Krentz, N.A.J., Kleiner, S., Jain, D., Richard, A.M., Abaitua, F., Beer, N.L., et al. (2019). Loss of ZnT8 function protects against diabetes by enhanced insulin secretion. *Nat. Genet.* 51, 1596–1606.
35. Amin, S., Cook, B., Zhou, T., Ghazizadeh, Z., Lis, R., Zhang, T., Khalaj, M., Crespo, M., Perera, M., Xiang, J.Z., et al. (2018). Discovery of a drug candidate for GLIS3-associated diabetes. *Nat. Commun.* 9, 2681.
36. Millman, J.R., Xie, C., Van Dervort, A., Gürler, M., Pagliuca, F.W., and Melton, D.A. (2016). Generation of stem cell-derived β -cells from patients with type 1 diabetes. *Nat. Commun.* 7, 11463.
37. Thatava, T., Kudva, Y.C., Edukulla, R., Squillace, K., Genebriera De Lamo, J., Krotova Khan, Y., Sakuma, T., Ohmine, S., Terzic, A., and Ikeda, Y. (2013). Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. *Mol. Ther.* 21, 228–239.
38. Lithovius, V., Saarimäki-Vire, J., Balboa, D., Ibrahim, H., Montaser, H., Barsby, T., and Otonkoski, T. (2021). SUR1-mutant iPS cell-derived islets recapitulate the pathophysiology of congenital hyperinsulinism. *Diabetologia* 64, 630–640.
39. Cardenas-Diaz, F.L., Osorio-Quintero, C., Diaz-Miranda, M.A., Kishore, S., Leavens, K., Jobaliya, C., Stanescu, D., Ortiz-Gonzalez, X., Yoon, C., Chen, C.S., et al. (2019). Modeling Monogenic Diabetes using Human ESCs Reveals Developmental and Metabolic Deficiencies Caused by Mutations in HNF1A. *Cell Stem Cell* 25, 273–289.e5.
40. Kishore, S., De Franco, E., Cardenas-Diaz, F.L., Letourneau-Freiberg, L.R., Sanyoura, M., Osorio-Quintero, C., French, D.L., Greeley, S.A.W., Hattersley, A.T., and Gadue, P. (2020). A Non-Coding Disease Modifier of Pancreatic Agenesis Identified by Genetic Correction in a Patient-Derived iPSC Line. *Cell Stem Cell* 27, 137–146.e6.
41. Stepniewski, J., Kachamakova-Trojanowska, N., Ogródek, D., Szopa, M., Matłok, M., Beilharz, M., et al. (2015). Induced pluripotent stem cells as a model for diabetes investigation. *Sci Rep.* 5, 8597. <https://doi.org/10.1038/srep08597>.
42. Shang, L., Hua, H., Foo, K., Martinez, H., Watanabe, K., Zimmer, M., Kahler, D.J., Freeby, M., Chung, W., LeDuc, C., et al. (2014). β -cell dysfunction due to increased ER stress in a stem cell model of Wolfram syndrome. *Diabetes* 63, 923–933.
43. Teo, A.K., Windmueller, R., Johansson, B.B., Dirice, E., Njolstad, P.R., Tjora, E., et al. (2013). Derivation of Human Induced Pluripotent Stem Cells from Patients with Maturity Onset Diabetes of the Young. *J Biol Chem* 288, 5353–5356. <https://doi.org/10.1074/jbc.C112.428979>.
44. Steiner, D.J., Kim, A., Miller, K., and Hara, M. (2010). Pancreatic islet plasticity: interspecies comparison of islet architecture and composition. *Islets* 2, 135–145.
45. Eizirik, D.L., Pipeleers, D.G., Ling, Z., Welsh, N., Hellerström, C., and Andersson, A. (1994). Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury. *Proc. Natl. Acad. Sci. USA* 91, 9253–9256.
46. Segerstolpe, Å., Palasantza, A., Eliasson, P., Andersson, E.M., Andréasson, A.C., Sun, X., Picelli, S., Sabirsh, A., Clausen, M., Bjursell, M.K., et al. (2016). Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. *Cell Metab.* 24, 593–607.
47. Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., et al. (2007). A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature* 445, 881–885.
48. Xin, Y., Dominguez Gutierrez, G., Okamoto, H., Kim, J., Lee, A.H., Adler, C., Ni, M., Yancopoulos, G.D., Murphy, A.J., and Gromada, J. (2018). Pseudotime ordering of single human β -cells reveals states of insulin production and unfolded protein response. *Diabetes* 67, 1783–1794.
49. Simsek, S., Zhou, T., Robinson, C.L., Tsai, S.Y., Crespo, M., Amin, S., Lin, X., Hon, J., Evans, T., and Chen, S. (2016). Modeling Cystic Fibrosis Using Pluripotent Stem Cell-Derived Human Pancreatic Ductal Epithelial Cells. *Stem Cells Transl. Med.* 5, 572–579.
50. Harris, A.G., Letourneau, L.R., and Greeley, S.A.W. (2018). Monogenic diabetes: the impact of making the right diagnosis. *Curr. Opin. Pediatr.* 30, 558–567.
51. Hrvatin, S., O'Donnell, C.W., Deng, F., Millman, J.R., Pagliuca, F.W., Dilorio, P., Rezania, A., Gifford, D.K., and Melton, D.A. (2014). Differentiated human stem cells resemble fetal, not adult, β cells. *Proc. Natl. Acad. Sci. USA* 111, 3038–3043.
52. Augsornworawat, P., and Millman, J.R. (2020). Single-cell RNA sequencing for engineering and studying human islets. *Curr. Opin. Biomed. Eng.* 16, 27–33.
53. Muraro, M.J., Dharmadhikari, G., Grün, D., Groen, N., Dielen, T., Jansen, E., van Gurp, L., Engelse, M.A., Carlotti, F., de Koning, E.J.P., and van Ouwerkerk, A. (2016). A single-cell transcriptome atlas of the human pancreas. *Cell Syst.* 3, 385–394.e3.
54. Krentz, N.A.J., Lee, M.Y.Y., Xu, E.E., Sproul, S.L.J., Maslova, A., Sasaki, S., and Lynn, F.C. (2018). Single-Cell Transcriptome Profiling of Mouse and hESC-Derived Pancreatic Progenitors. *Stem Cell Reports* 11, 1551–1564.
55. Demine, S., Schiavo, A.A., Marín-Cañas, S., Marchetti, P., Cnop, M., and Eizirik, D.L. (2020). Pro-inflammatory cytokines induce cell death,

- inflammatory responses, and endoplasmic reticulum stress in human iPSC-derived beta cells. *Stem Cell Res. Ther.* 11, 7.
56. Fonseca, S.G., Gromada, J., and Urano, F. (2011). Endoplasmic reticulum stress and pancreatic β -cell death. *Trends Endocrinol. Metab.* 22, 266–274.
 57. Hakonen, E., Chandra, V., Fogarty, C.L., Yu, N.Y., Ustinov, J., Katayama, S., Galli, E., Danilova, T., Lindholm, P., Virtainen, A., et al. (2018). MANF protects human pancreatic beta cells against stress-induced cell death. *Diabetologia* 61, 2202–2214.
 58. Misun, P.M., Yesildag, B., Forschler, F., Neelakandhan, A., Rousset, N., Biernath, A., Hierlemann, A., and Frey, O. (2020). In Vitro Platform for Studying Human Insulin Release Dynamics of Single Pancreatic Islet Microtissues at High Resolution. *Adv. Biosyst.* 4, e1900291.
 59. Lenguito, G., Chaimov, D., Weitz, J.R., Rodriguez-Diaz, R., Rawal, S.A., Tamayo-Garcia, A., Caicedo, A., Stabler, C.L., Buchwald, P., and Agarwal, A. (2017). Resealable, optically accessible, PDMS-free fluidic platform for ex vivo interrogation of pancreatic islets. *Lab Chip* 17, 772–781.
 60. Jun, Y., Lee, J., Choi, S., Yang, J.H., Sander, M., Chung, S., and Lee, S.H. (2019). In vivo-mimicking microfluidic perfusion culture of pancreatic islet spheroids. *Sci. Adv.* 5, eaax4520.
 61. Sankar, K.S., Green, B.J., Crocker, A.R., Verity, J.E., Altamentova, S.M., and Rocheleau, J.V. (2011). Culturing pancreatic islets in microfluidic flow enhances morphology of the associated endothelial cells. *PLoS ONE* 6, e24904.
 62. Glieberman, A.L., Pope, B.D., Zimmerman, J.F., Liu, Q., Ferrier, J.P., Kent, J.H.R., Schrell, A.M., Mukhitov, N., Shores, K.L., Tepole, A.B., et al. (2019). Synchronized stimulation and continuous insulin sensing in a microfluidic human islet on a chip designed for scalable manufacturing. *Lab Chip* 19, 2993–3010.
 63. Ishahak, M., Birman, L., Carbonero, D., et al. (2019). Integrated platform for operating and interrogating organs-on-chips. *Anal. Methods* 11, 5645–5651.
 64. Wesolowska-Andersen, A., Jensen, R.R., Alcántara, M.P., Beer, N.L., Duff, C., Nylander, V., Gosden, M., Witty, L., Bowden, R., McCarthy, M.I., et al. (2020). Analysis of Differentiation Protocols Defines a Common Pancreatic Progenitor Molecular Signature and Guides Refinement of Endocrine Differentiation. *Stem Cell Reports* 14, 138–153.
 65. Mahaddalkar, P.U., Scheibner, K., Pfluger, S., Ansarullah, S., Sterr, M., Beckenbauer, J., Irmler, M., Beckers, J., Knöbel, S., and Lickert, H. (2020). Generation of pancreatic β cells from CD177⁺ anterior definitive endoderm. *Nat. Biotechnol.* 38, 1061–1072.
 66. Li, X., Yang, K.Y., Chan, V.W., Leung, K.T., Zhang, X.B., Wong, A.S., Chong, C.C.N., Wang, C.C., Ku, M., and Lui, K.O. (2020). Single-Cell RNA-Seq Reveals that CD9 Is a Negative Marker of Glucose-Responsive Pancreatic β -like Cells Derived from Human Pluripotent Stem Cells. *Stem Cell Reports* 15, 1111–1126.
 67. Zhu, Y., Liu, Q., Zhou, Z., and Ikeda, Y. (2017). PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration. *Stem Cell Res. Ther.* 8, 240.
 68. Eichstadt, S., Barriga, M., Ponakala, A., Teng, C., Nguyen, N.T., Siprashvili, Z., Nazaroff, J., Gorell, E.S., Chiou, A.S., Taylor, L., et al. (2019). Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. *JCI Insight* 4, 130554.
 69. Río, P., Navarro, S., Wang, W., Sánchez-Domínguez, R., Pujol, R.M., Segovia, J.C., Bogliolo, M., Merino, E., Wu, N., Salgado, R., et al. (2019). Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. *Nat. Med.* 25, 1396–1401.
 70. Lee, J., Bayarsaikhan, D., Bayarsaikhan, G., Kim, J.S., Schwarzbach, E., and Lee, B. (2020). Recent advances in genome editing of stem cells for drug discovery and therapeutic application. *Pharmacol. Ther.* 209, 107501.
 71. Sackett, S.D., Rodriguez, A., and Odorico, J.S. (2017). The nexus of stem cell-derived beta-cells and genome engineering. *Rev. Diabet. Stud.* 14, 39–50.
 72. Yoshihara, E., O'Connor, C., Gasser, E., Wei, Z., Oh, T.G., Tseng, T.W., Wang, D., Cayabyab, F., Dai, Y., Yu, R.T., et al. (2020). Immune-evasive human islet-like organoids ameliorate diabetes. *Nature* 586, 606–611.
 73. Deuse, T., Hu, X., Gravina, A., Wang, D., Tedashvili, G., De, C., Thayer, W.O., Wahl, A., Garcia, J.V., Reichensperger, H., et al. (2019). Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. *Nat. Biotechnol.* 37, 252–258.
 74. Millman, J.R., and Pagliuca, F.W. (2017). Autologous Pluripotent Stem Cell-Derived β -Like Cells for Diabetes Cellular Therapy. *Diabetes* 66, 1111–1120.
 75. Stock, A.A., Manzoli, V., De Toni, T., Abreu, M.M., Poh, Y.C., Ye, L., Roose, A., Pagliuca, F.W., Thanos, C., Ricordi, C., and Tomei, A.A. (2020). Conformal Coating of Stem Cell-Derived Islets for β Cell Replacement in Type 1 Diabetes. *Stem Cell Reports* 14, 91–104.
 76. Zhu, S., Russ, H.A., Wang, X., Zhang, M., Ma, T., Xu, T., Tang, S., Hebrok, M., and Ding, S. (2016). Human pancreatic beta-like cells converted from fibroblasts. *Nat. Commun.* 7, 10080.
 77. Saber, N., Bruin, J.E., O'Dwyer, S., Schuster, H., Rezania, A., and Kieffer, T.J. (2018). Sex Differences in Maturation of Human Embryonic Stem Cell-Derived β Cells in Mice. *Endocrinology* 159, 1827–1841.
 78. Bruin, J.E., Rezania, A., Xu, J., Narayan, K., Fox, J.K., O'Neil, J.J., and Kieffer, T.J. (2013). Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice. *Diabetologia* 56, 1987–1998.
 79. Robert, T., De Mesmaeker, I., Stangé, G.M., Suenens, K.G., Ling, Z., Kroon, E.J., and Pipeleers, D.G. (2018). Functional beta cell mass from device-encapsulated hESC-derived pancreatic endoderm achieving metabolic control. *Stem Cell Reports* 10, 739–750.
 80. Chang, R., Faleo, G., Russ, H.A., Parent, A.V., Elledge, S.K., Bernards, D.A., Allen, J.L., Villanueva, K., Hebrok, M., Tang, Q., and Desai, T.A. (2017). Nanoporous immunoprotective device for stem-cell-derived β -cell replacement therapy. *ACS Nano* 11, 7747–7757.
 81. Desai, T., and Shea, L.D. (2017). Advances in islet encapsulation technologies. *Nat. Rev. Drug Discov.* 16, 338–350.
 82. Nathan, D.M. (1993). Long-term complications of diabetes mellitus. *N. Engl. J. Med.* 328, 1676–1685.
 83. Scharp, D.W., Lacy, P.E., Santiago, J.V., McCullough, C.S., Weide, L.G., Falqui, L., Marchetti, P., Gingerich, R.L., Jaffe, A.S., Cryer, P.E., et al. (1990). Insulin independence after islet transplantation into type I diabetic patient. *Diabetes* 39, 515–518.
 84. Shapiro, A.M., Ricordi, C., Hering, B.J., Auchincloss, H., Lindblad, R., Robertson, R.P., Secchi, A., Brendel, M.D., Berney, T., Brennan, D.C., et al. (2006). International trial of the Edmonton protocol for islet transplantation. *N. Engl. J. Med.* 355, 1318–1330.
 85. Shapiro, A.M.J., Lakey, J.R.T., Ryan, E.A., Korbutt, G.S., Toth, E., Warnecke, G.L., Kneteman, N.M., and Rajotte, R.V. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N. Engl. J. Med.* 343, 230–238.
 86. Deuse, T., Hu, X., Agbor-Enoh, S., Koch, M., Spitzer, M.H., Gravina, A., Alawi, M., Marishta, A., Peters, B., Kosaloglu-Yalcin, Z., et al. (2019). De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neopeptides in mice and humans. *Nat. Biotechnol.* 37, 1137–1144.
 87. de Rham, C., and Villard, J. (2014). Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy. *J. Immunol. Res.* 2014, 518135.
 88. Park, Y.J., Jeon, S.H., Kim, H.K., Suh, E.J., Choi, S.J., Kim, S., and Kim, H.O. (2020). Human induced pluripotent stem cell line banking for the production of rare blood type erythrocytes. *J. Transl. Med.* 18, 236.

89. Turinotto, V., Orlando, L., and Giachino, C. (2017). Induced Pluripotent Stem Cells: Advances in the Quest for Genetic Stability during Reprogramming Process. *Int. J. Mol. Sci.* **18**, E1952.
90. Penney, J., Ralvenius, W.T., and Tsai, L.H. (2020). Modeling Alzheimer's disease with iPSC-derived brain cells. *Mol. Psychiatry* **25**, 148–167.
91. Ng, A.H.M., Khoshakhlagh, P., Rojo Arias, J.E., Pasquini, G., Wang, K., Swiersy, A., Shipman, S.L., Appleton, E., Kiaee, K., Kohman, R.E., et al. (2020). A comprehensive library of human transcription factors for cell fate engineering. *Nat. Biotechnol.* <https://doi.org/10.1038/s41587-020-0742-6>.
92. Cardenas-Diaz, F.L., Leavens, K.F., Kishore, S., Osorio-Quintero, C., Chen, Y.J., Stanger, B.Z., Wang, P., French, D., and Gadue, P. (2020). A Dual Reporter EndoC-βH1 Human β-Cell Line for Efficient Quantification of Calcium Flux and Insulin Secretion. *Endocrinology* **161**, bcaa005.
93. Kracht, M.J.L., de Koning, E.J.P., Hoeben, R.C., Roep, B.O., and Zaldumbide, A. (2018). Bioluminescent reporter assay for monitoring ER stress in human beta cells. *Sci. Rep.* **8**, 17738.
94. Burns, S.M., Vetere, A., Walpita, D., Dančík, V., Khodier, C., Perez, J., Clemons, P.A., Wagner, B.K., and Altshuler, D. (2015). High-throughput luminescent reporter of insulin secretion for discovering regulators of pancreatic Beta-cell function. *Cell Metab.* **21**, 126–137.